Theriva Biologics announces 1-for-30 reverse stock split effective Dec. 1
TOVX•Theriva Biologics will implement a 1-for-30 reverse stock split effective Dec. 1, 2026, with split-adjusted trading beginning Dec. 2. Outstanding common shares will decline from 45,892,668 to approximately 1,529,756, excluding fractional-share adjustments.
1. Split details
Theriva Biologics will implement a 1-for-30 reverse stock split effective at 11:59 p.m. Eastern Time on Dec. 1, 2026. Split-adjusted trading will begin Dec. 2 on NYSE American; the company said the split aims to meet the exchange’s per-share price requirements.
2. Share count changes
Outstanding common shares will decline from 45,892,668 to approximately 1,529,756, excluding fractional-share adjustments. Authorized common shares will decrease from 350,000,000 to 11,666,666, and fractional shares will be rounded up to the next whole share.




